Cite
HARVARD Citation
Verma, S. et al. (2022). Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet. 10 (1), pp. 35-45. [Online].